#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=In many clinical specialties , there exists a high variety of image modalities that clinicians typically use to analyze the patient ’s condition and aid in the diagnostic process .
3-1	17-19	In	_	_	_	_
3-2	20-24	many	abstract[3]	new[3]	_	_
3-3	25-33	clinical	abstract[3]	new[3]	_	_
3-4	34-45	specialties	abstract[3]	new[3]	_	_
3-5	46-47	,	_	_	_	_
3-6	48-53	there	_	_	_	_
3-7	54-60	exists	_	_	_	_
3-8	61-62	a	abstract[4]	new[4]	_	_
3-9	63-67	high	abstract[4]	new[4]	_	_
3-10	68-75	variety	abstract[4]	new[4]	_	_
3-11	76-78	of	abstract[4]	new[4]	_	_
3-12	79-84	image	abstract[4]|object|abstract[6]	new[4]|new|new[6]	coref|coref|coref|coref	6-2|7-4[49_6]|6-2|7-4[49_6]
3-13	85-95	modalities	abstract[4]|abstract[6]	new[4]|new[6]	_	_
3-14	96-100	that	_	_	_	_
3-15	101-111	clinicians	person	new	_	_
3-16	112-121	typically	_	_	_	_
3-17	122-125	use	_	_	_	_
3-18	126-128	to	_	_	_	_
3-19	129-136	analyze	_	_	_	_
3-20	137-140	the	abstract[9]	new[9]	_	_
3-21	141-148	patient	person[8]|abstract[9]	new[8]|new[9]	coref	9-28[71_8]
3-22	149-151	’s	person[8]|abstract[9]	new[8]|new[9]	_	_
3-23	152-161	condition	abstract[9]	new[9]	_	_
3-24	162-165	and	_	_	_	_
3-25	166-169	aid	_	_	_	_
3-26	170-172	in	_	_	_	_
3-27	173-176	the	event[10]	new[10]	coref	21-10[161_10]
3-28	177-187	diagnostic	event[10]	new[10]	_	_
3-29	188-195	process	event[10]	new[10]	_	_
3-30	196-197	.	_	_	_	_

#Text=Given the importance of technology at present , namely , its inclusion in different areas to improve an expert ’s work , many computational systems have been implemented to facilitate this clinical processes .
4-1	198-203	Given	_	_	_	_
4-2	204-207	the	abstract[11]|person[15]	new[11]|new[15]	_	_
4-3	208-218	importance	abstract[11]|person[15]	new[11]|new[15]	_	_
4-4	219-221	of	abstract[11]|person[15]	new[11]|new[15]	_	_
4-5	222-232	technology	abstract[11]|abstract|person[15]	new[11]|new|new[15]	ana	4-11
4-6	233-235	at	abstract[11]|person[15]	new[11]|new[15]	_	_
4-7	236-243	present	abstract[11]|time|person[15]	new[11]|new|new[15]	_	_
4-8	244-245	,	person[15]	new[15]	_	_
4-9	246-252	namely	person[15]	new[15]	_	_
4-10	253-254	,	person[15]	new[15]	_	_
4-11	255-258	its	abstract|person[15]	giv|new[15]	_	_
4-12	259-268	inclusion	person[15]	new[15]	_	_
4-13	269-271	in	person[15]	new[15]	_	_
4-14	272-281	different	person[15]|place[16]	new[15]|new[16]	coref	6-25[36_16]
4-15	282-287	areas	person[15]|place[16]	new[15]|new[16]	_	_
4-16	288-290	to	_	_	_	_
4-17	291-298	improve	_	_	_	_
4-18	299-301	an	abstract[18]	new[18]	_	_
4-19	302-308	expert	person[17]|abstract[18]	new[17]|new[18]	coref	5-19[27_17]
4-20	309-311	’s	person[17]|abstract[18]	new[17]|new[18]	_	_
4-21	312-316	work	abstract[18]	new[18]	_	_
4-22	317-318	,	_	_	_	_
4-23	319-323	many	object[19]	new[19]	coref	6-53[47_19]
4-24	324-337	computational	object[19]	new[19]	_	_
4-25	338-345	systems	object[19]	new[19]	_	_
4-26	346-350	have	_	_	_	_
4-27	351-355	been	_	_	_	_
4-28	356-367	implemented	_	_	_	_
4-29	368-370	to	_	_	_	_
4-30	371-381	facilitate	_	_	_	_
4-31	382-386	this	abstract[20]	new[20]	coref	15-30[118_20]
4-32	387-395	clinical	abstract[20]	new[20]	_	_
4-33	396-405	processes	abstract[20]	new[20]	_	_
4-34	406-407	.	_	_	_	_

#Text=This automatization of different clinical manual tasks provide solutions and improvements that are characterized by desirable properties that the expert cannot offer such as determinism , repeatability or objectivity .
5-1	408-412	This	abstract[21]	new[21]	_	_
5-2	413-427	automatization	abstract[21]	new[21]	_	_
5-3	428-430	of	abstract[21]	new[21]	_	_
5-4	431-440	different	abstract[21]|abstract[23]	new[21]|new[23]	_	_
5-5	441-449	clinical	abstract[21]|abstract[23]	new[21]|new[23]	_	_
5-6	450-456	manual	abstract[21]|object|abstract[23]	new[21]|new|new[23]	coref	25-6
5-7	457-462	tasks	abstract[21]|abstract[23]	new[21]|new[23]	_	_
5-8	463-470	provide	_	_	_	_
5-9	471-480	solutions	abstract	new	_	_
5-10	481-484	and	_	_	_	_
5-11	485-497	improvements	abstract	new	_	_
5-12	498-502	that	_	_	_	_
5-13	503-506	are	_	_	_	_
5-14	507-520	characterized	_	_	_	_
5-15	521-523	by	_	_	_	_
5-16	524-533	desirable	abstract[26]	new[26]	_	_
5-17	534-544	properties	abstract[26]	new[26]	_	_
5-18	545-549	that	abstract[26]	new[26]	_	_
5-19	550-553	the	abstract[26]|person[27]	new[26]|giv[27]	_	_
5-20	554-560	expert	abstract[26]|person[27]	new[26]|giv[27]	_	_
5-21	561-567	cannot	abstract[26]	new[26]	_	_
5-22	568-573	offer	abstract[26]	new[26]	_	_
5-23	574-578	such	_	_	_	_
5-24	579-581	as	_	_	_	_
5-25	582-593	determinism	abstract	new	_	_
5-26	594-595	,	_	_	_	_
5-27	596-609	repeatability	abstract	new	coref	25-24[197_0]
5-28	610-612	or	_	_	_	_
5-29	613-624	objectivity	abstract	new	_	_
5-30	625-626	.	_	_	_	_

#Text=Regarding image analysis , over the years , many computational proposals have been presented based on computer vision techniques that are exploited to analyze relevant areas of the images of interest , measure relevant parameters and monitor their evolution and potential variations , which is the typical procedure that is used in many Computer Aided Diagnostic ( CAD ) systems .
6-1	627-636	Regarding	_	_	_	_
6-2	637-642	image	object|abstract[32]	giv|new[32]	coref|coref|coref|coref	7-5|12-17[99_32]|7-5|12-17[99_32]
6-3	643-651	analysis	abstract[32]	new[32]	_	_
6-4	652-653	,	_	_	_	_
6-5	654-658	over	_	_	_	_
6-6	659-662	the	_	_	_	_
6-7	663-668	years	_	_	_	_
6-8	669-670	,	_	_	_	_
6-9	671-675	many	abstract[33]	new[33]	_	_
6-10	676-689	computational	abstract[33]	new[33]	_	_
6-11	690-699	proposals	abstract[33]	new[33]	_	_
6-12	700-704	have	_	_	_	_
6-13	705-709	been	_	_	_	_
6-14	710-719	presented	_	_	_	_
6-15	720-725	based	_	_	_	_
6-16	726-728	on	_	_	_	_
6-17	729-737	computer	abstract[35]	new[35]	_	_
6-18	738-744	vision	abstract|abstract[35]	new|new[35]	coref	17-19
6-19	745-755	techniques	abstract[35]	new[35]	_	_
6-20	756-760	that	_	_	_	_
6-21	761-764	are	_	_	_	_
6-22	765-774	exploited	_	_	_	_
6-23	775-777	to	_	_	_	_
6-24	778-785	analyze	_	_	_	_
6-25	786-794	relevant	place[36]	giv[36]	_	_
6-26	795-800	areas	place[36]	giv[36]	_	_
6-27	801-803	of	place[36]	giv[36]	_	_
6-28	804-807	the	place[36]|object[37]	giv[36]|new[37]	coref	25-10[193_37]
6-29	808-814	images	place[36]|object[37]	giv[36]|new[37]	_	_
6-30	815-817	of	place[36]|object[37]	giv[36]|new[37]	_	_
6-31	818-826	interest	place[36]|object[37]	giv[36]|new[37]	_	_
6-32	827-828	,	_	_	_	_
6-33	829-836	measure	_	_	_	_
6-34	837-845	relevant	abstract[38]	new[38]	ana	6-38[0_38]
6-35	846-856	parameters	abstract[38]	new[38]	_	_
6-36	857-860	and	_	_	_	_
6-37	861-868	monitor	_	_	_	_
6-38	869-874	their	abstract|abstract[40]	giv|new[40]	_	_
6-39	875-884	evolution	abstract[40]	new[40]	_	_
6-40	885-888	and	_	_	_	_
6-41	889-898	potential	abstract[41]	new[41]	_	_
6-42	899-909	variations	abstract[41]	new[41]	_	_
6-43	910-911	,	_	_	_	_
6-44	912-917	which	_	_	_	_
6-45	918-920	is	_	_	_	_
6-46	921-924	the	abstract[42]	new[42]	_	_
6-47	925-932	typical	abstract[42]	new[42]	_	_
6-48	933-942	procedure	abstract[42]	new[42]	_	_
6-49	943-947	that	_	_	_	_
6-50	948-950	is	_	_	_	_
6-51	951-955	used	_	_	_	_
6-52	956-958	in	_	_	_	_
6-53	959-963	many	abstract[45]|object[47]	new[45]|giv[47]	appos|appos	6-58[0_45]|6-58[0_45]
6-54	964-972	Computer	object|abstract[45]|object[47]	new|new[45]|giv[47]	_	_
6-55	973-978	Aided	person|abstract[45]|object[47]	new|new[45]|giv[47]	_	_
6-56	979-989	Diagnostic	abstract[45]|object[47]	new[45]|giv[47]	_	_
6-57	990-991	(	object[47]	giv[47]	_	_
6-58	992-995	CAD	abstract|object[47]	giv|giv[47]	_	_
6-59	996-997	)	object[47]	giv[47]	_	_
6-60	998-1005	systems	object[47]	giv[47]	_	_
6-61	1006-1007	.	_	_	_	_

#Text=In ophthalmology , different image modalities have increased in popularity over the last years .
7-1	1008-1010	In	_	_	_	_
7-2	1011-1024	ophthalmology	_	_	_	_
7-3	1025-1026	,	_	_	_	_
7-4	1027-1036	different	abstract[49]	giv[49]	_	_
7-5	1037-1042	image	abstract|abstract[49]	giv|giv[49]	coref	8-13
7-6	1043-1053	modalities	abstract[49]	giv[49]	_	_
7-7	1054-1058	have	_	_	_	_
7-8	1059-1068	increased	_	_	_	_
7-9	1069-1071	in	_	_	_	_
7-10	1072-1082	popularity	abstract	new	_	_
7-11	1083-1087	over	_	_	_	_
7-12	1088-1091	the	time[51]	new[51]	_	_
7-13	1092-1096	last	time[51]	new[51]	_	_
7-14	1097-1102	years	time[51]	new[51]	_	_
7-15	1103-1104	.	_	_	_	_

#Text=The color fundus retinography is the most traditional and widely extended ophthalmic image modality , that allows the direct visualization of the eye fundus and their possible pathological visible structures .
8-1	1105-1108	The	event[53]|object[54]	new[53]|new[54]	coref|coref|coref|coref	8-6[56_54]|8-22[59_53]|8-6[56_54]|8-22[59_53]
8-2	1109-1114	color	abstract|event[53]|object[54]	new|new[53]|new[54]	_	_
8-3	1115-1121	fundus	event[53]|object[54]	new[53]|new[54]	_	_
8-4	1122-1134	retinography	object[54]	new[54]	_	_
8-5	1135-1137	is	_	_	_	_
8-6	1138-1141	the	object[56]	giv[56]	coref	11-10[84_56]
8-7	1142-1146	most	object[56]	giv[56]	_	_
8-8	1147-1158	traditional	object[56]	giv[56]	_	_
8-9	1159-1162	and	object[56]	giv[56]	_	_
8-10	1163-1169	widely	object[56]	giv[56]	_	_
8-11	1170-1178	extended	object[56]	giv[56]	_	_
8-12	1179-1189	ophthalmic	object[56]	giv[56]	_	_
8-13	1190-1195	image	object|object[56]	giv|giv[56]	coref	11-12
8-14	1196-1204	modality	object[56]	giv[56]	_	_
8-15	1205-1206	,	_	_	_	_
8-16	1207-1211	that	_	_	_	_
8-17	1212-1218	allows	_	_	_	_
8-18	1219-1222	the	abstract[57]	new[57]	_	_
8-19	1223-1229	direct	abstract[57]	new[57]	_	_
8-20	1230-1243	visualization	abstract[57]	new[57]	_	_
8-21	1244-1246	of	abstract[57]	new[57]	_	_
8-22	1247-1250	the	abstract[57]|event[59]|abstract[60]	new[57]|giv[59]|new[60]	_	_
8-23	1251-1254	eye	abstract[57]|object|event[59]|abstract[60]	new[57]|new|giv[59]|new[60]	coref	14-12
8-24	1255-1261	fundus	abstract[57]|event[59]|abstract[60]	new[57]|giv[59]|new[60]	_	_
8-25	1262-1265	and	abstract[57]|abstract[60]	new[57]|new[60]	_	_
8-26	1266-1271	their	abstract[57]|abstract[60]|abstract[61]	new[57]|new[60]|new[61]	_	_
8-27	1272-1280	possible	abstract[57]|abstract[60]|abstract[61]	new[57]|new[60]|new[61]	_	_
8-28	1281-1293	pathological	abstract[57]|abstract[60]|abstract[61]	new[57]|new[60]|new[61]	_	_
8-29	1294-1301	visible	abstract[57]|abstract[60]|abstract[61]	new[57]|new[60]|new[61]	_	_
8-30	1302-1312	structures	abstract[57]|abstract[60]|abstract[61]	new[57]|new[60]|new[61]	_	_
8-31	1313-1314	.	_	_	_	_

#Text=Being an invasive capture technique , the Fluorescein Angiography ( FA ) provides an enhanced visualization of the retinal vascular structure by injecting a dye contrast into the patient .
9-1	1315-1320	Being	_	_	_	_
9-2	1321-1323	an	abstract[63]	new[63]	_	_
9-3	1324-1332	invasive	abstract[63]	new[63]	_	_
9-4	1333-1340	capture	event|abstract[63]	new|new[63]	_	_
9-5	1341-1350	technique	abstract[63]	new[63]	_	_
9-6	1351-1352	,	_	_	_	_
9-7	1353-1356	the	abstract[65]	new[65]	appos	9-11[0_65]
9-8	1357-1368	Fluorescein	person|abstract[65]	new|new[65]	_	_
9-9	1369-1380	Angiography	abstract[65]	new[65]	_	_
9-10	1381-1382	(	_	_	_	_
9-11	1383-1385	FA	abstract	giv	coref	11-7
9-12	1386-1387	)	_	_	_	_
9-13	1388-1396	provides	_	_	_	_
9-14	1397-1399	an	abstract[67]	new[67]	coref	11-22[88_67]
9-15	1400-1408	enhanced	abstract[67]	new[67]	_	_
9-16	1409-1422	visualization	abstract[67]	new[67]	_	_
9-17	1423-1425	of	abstract[67]	new[67]	_	_
9-18	1426-1429	the	abstract[67]|abstract[68]	new[67]|new[68]	_	_
9-19	1430-1437	retinal	abstract[67]|abstract[68]	new[67]|new[68]	_	_
9-20	1438-1446	vascular	abstract[67]|abstract[68]	new[67]|new[68]	_	_
9-21	1447-1456	structure	abstract[67]|abstract[68]	new[67]|new[68]	_	_
9-22	1457-1459	by	_	_	_	_
9-23	1460-1469	injecting	_	_	_	_
9-24	1470-1471	a	abstract[70]	new[70]	_	_
9-25	1472-1475	dye	abstract|abstract[70]	new|new[70]	_	_
9-26	1476-1484	contrast	abstract[70]	new[70]	_	_
9-27	1485-1489	into	_	_	_	_
9-28	1490-1493	the	person[71]	giv[71]	coref	19-8[147_71]
9-29	1494-1501	patient	person[71]	giv[71]	_	_
9-30	1502-1503	.	_	_	_	_

#Text=With the Optical Coherence Tomography ( OCT ) , we can visualize and analyze volumetric scans of the inner retinal layers , non-invasively and in real time .
10-1	1504-1508	With	_	_	_	_
10-2	1509-1512	the	object[74]	new[74]	_	_
10-3	1513-1520	Optical	substance|object[74]	new|new[74]	coref	11-27
10-4	1521-1530	Coherence	abstract|object[74]	new|new[74]	coref	11-27[90_0]
10-5	1531-1541	Tomography	object[74]	new[74]	_	_
10-6	1542-1543	(	_	_	_	_
10-7	1544-1547	OCT	time	new	coref	11-3[80_0]
10-8	1548-1549	)	_	_	_	_
10-9	1550-1551	,	_	_	_	_
10-10	1552-1554	we	person	acc	_	_
10-11	1555-1558	can	_	_	_	_
10-12	1559-1568	visualize	_	_	_	_
10-13	1569-1572	and	_	_	_	_
10-14	1573-1580	analyze	_	_	_	_
10-15	1581-1591	volumetric	event[77]	new[77]	_	_
10-16	1592-1597	scans	event[77]	new[77]	_	_
10-17	1598-1600	of	event[77]	new[77]	_	_
10-18	1601-1604	the	event[77]|object[78]	new[77]|new[78]	coref	13-11[105_78]
10-19	1605-1610	inner	event[77]|object[78]	new[77]|new[78]	_	_
10-20	1611-1618	retinal	event[77]|object[78]	new[77]|new[78]	_	_
10-21	1619-1625	layers	event[77]|object[78]	new[77]|new[78]	_	_
10-22	1626-1627	,	event[77]	new[77]	_	_
10-23	1628-1642	non-invasively	event[77]	new[77]	_	_
10-24	1643-1646	and	event[77]	new[77]	_	_
10-25	1647-1649	in	event[77]	new[77]	_	_
10-26	1650-1654	real	event[77]|abstract[79]	new[77]|new[79]	_	_
10-27	1655-1659	time	event[77]|abstract[79]	new[77]|new[79]	_	_
10-28	1660-1661	.	_	_	_	_

#Text=Based on the OCT and the FA characteristics , a new image modality appeared , combining both the OCT benefits and the FA visualization : the Optical Coherence Tomography by Angiography ( OCTA ) .
11-1	1662-1667	Based	_	_	_	_
11-2	1668-1670	on	_	_	_	_
11-3	1671-1674	the	time[80]	giv[80]	coref	11-19[0_80]
11-4	1675-1678	OCT	time[80]	giv[80]	_	_
11-5	1679-1682	and	_	_	_	_
11-6	1683-1686	the	abstract[82]	new[82]	coref	26-15[209_82]
11-7	1687-1689	FA	abstract|abstract[82]	giv|new[82]	coref	11-23
11-8	1690-1705	characteristics	abstract[82]	new[82]	_	_
11-9	1706-1707	,	_	_	_	_
11-10	1708-1709	a	object[84]	giv[84]	coref	12-4[97_84]
11-11	1710-1713	new	object[84]	giv[84]	_	_
11-12	1714-1719	image	object|object[84]	giv|giv[84]	coref	12-7
11-13	1720-1728	modality	object[84]	giv[84]	_	_
11-14	1729-1737	appeared	_	_	_	_
11-15	1738-1739	,	_	_	_	_
11-16	1740-1749	combining	_	_	_	_
11-17	1750-1754	both	abstract[86]	new[86]	_	_
11-18	1755-1758	the	abstract[86]	new[86]	_	_
11-19	1759-1762	OCT	time|abstract[86]	giv|new[86]	_	_
11-20	1763-1771	benefits	abstract[86]	new[86]	_	_
11-21	1772-1775	and	_	_	_	_
11-22	1776-1779	the	abstract[88]	giv[88]	appos	11-26[91_88]
11-23	1780-1782	FA	abstract|abstract[88]	giv|giv[88]	coref	11-31
11-24	1783-1796	visualization	abstract[88]	giv[88]	_	_
11-25	1797-1798	:	_	_	_	_
11-26	1799-1802	the	abstract[91]	giv[91]	coref	31-55[290_91]
11-27	1803-1810	Optical	substance|abstract[90]|abstract[91]	giv|giv[90]|giv[91]	_	_
11-28	1811-1820	Coherence	abstract[90]|abstract[91]	giv[90]|giv[91]	_	_
11-29	1821-1831	Tomography	abstract[91]	giv[91]	_	_
11-30	1832-1834	by	abstract[91]	giv[91]	_	_
11-31	1835-1846	Angiography	abstract[91]|abstract	giv[91]|giv	appos	11-33
11-32	1847-1848	(	_	_	_	_
11-33	1849-1853	OCTA	abstract	giv	coref	12-1
11-34	1854-1855	)	_	_	_	_
11-35	1856-1857	.	_	_	_	_

#Text=OCTA imaging constitutes the new ophthalmic image modality , and it is the first that allows an exhaustive and non-invasive vascular analysis of the retina .
12-1	1858-1862	OCTA	abstract|abstract[95]	giv|new[95]	ana|coref|ana|coref	12-11[0_95]|13-1|12-11[0_95]|13-1
12-2	1863-1870	imaging	abstract[95]	new[95]	_	_
12-3	1871-1882	constitutes	_	_	_	_
12-4	1883-1886	the	object[97]	giv[97]	coref	15-17[115_97]
12-5	1887-1890	new	object[97]	giv[97]	_	_
12-6	1891-1901	ophthalmic	object[97]	giv[97]	_	_
12-7	1902-1907	image	object|object[97]	giv|giv[97]	coref	15-21
12-8	1908-1916	modality	object[97]	giv[97]	_	_
12-9	1917-1918	,	_	_	_	_
12-10	1919-1922	and	_	_	_	_
12-11	1923-1925	it	abstract	giv	_	_
12-12	1926-1928	is	_	_	_	_
12-13	1929-1932	the	_	_	_	_
12-14	1933-1938	first	_	_	_	_
12-15	1939-1943	that	_	_	_	_
12-16	1944-1950	allows	_	_	_	_
12-17	1951-1953	an	abstract[99]	giv[99]	_	_
12-18	1954-1964	exhaustive	abstract[99]	giv[99]	_	_
12-19	1965-1968	and	abstract[99]	giv[99]	_	_
12-20	1969-1981	non-invasive	abstract[99]	giv[99]	_	_
12-21	1982-1990	vascular	abstract[99]	giv[99]	_	_
12-22	1991-1999	analysis	abstract[99]	giv[99]	_	_
12-23	2000-2002	of	abstract[99]	giv[99]	_	_
12-24	2003-2006	the	abstract[99]|object[100]	giv[99]|new[100]	_	_
12-25	2007-2013	retina	abstract[99]|object[100]	giv[99]|new[100]	_	_
12-26	2014-2015	.	_	_	_	_

#Text=OCTA accurately represents the vascularity of the foveal region within the retinal layers .
13-1	2016-2020	OCTA	object	giv	coref	15-15
13-2	2021-2031	accurately	_	_	_	_
13-3	2032-2042	represents	abstract	new	coref|none	14-1[106_0]|13-3[0_106]
13-4	2043-2046	the	abstract[102]	new[102]	_	_
13-5	2047-2058	vascularity	abstract[102]	new[102]	_	_
13-6	2059-2061	of	abstract[102]	new[102]	_	_
13-7	2062-2065	the	abstract[102]|place[104]	new[102]|new[104]	coref	30-71[264_104]
13-8	2066-2072	foveal	abstract[102]|place|place[104]	new[102]|new|new[104]	coref	24-17
13-9	2073-2079	region	abstract[102]|place[104]	new[102]|new[104]	_	_
13-10	2080-2086	within	abstract[102]|place[104]	new[102]|new[104]	_	_
13-11	2087-2090	the	abstract[102]|place[104]|object[105]	new[102]|new[104]|giv[105]	_	_
13-12	2091-2098	retinal	abstract[102]|place[104]|object[105]	new[102]|new[104]|giv[105]	_	_
13-13	2099-2105	layers	abstract[102]|place[104]|object[105]	new[102]|new[104]|giv[105]	_	_
13-14	2106-2107	.	_	_	_	_

#Text=This representation is extracted based on the blood movement in the eye microvasculature .
14-1	2108-2112	This	abstract[106]	new[106]	_	_
14-2	2113-2127	representation	abstract[106]	new[106]	_	_
14-3	2128-2130	is	_	_	_	_
14-4	2131-2140	extracted	_	_	_	_
14-5	2141-2146	based	_	_	_	_
14-6	2147-2149	on	_	_	_	_
14-7	2150-2153	the	abstract[108]	new[108]	_	_
14-8	2154-2159	blood	substance|abstract[108]	new|new[108]	coref	30-56
14-9	2160-2168	movement	abstract[108]	new[108]	_	_
14-10	2169-2171	in	abstract[108]	new[108]	_	_
14-11	2172-2175	the	abstract[108]|object[110]	new[108]|new[110]	_	_
14-12	2176-2179	eye	abstract[108]|object|object[110]	new[108]|giv|new[110]	_	_
14-13	2180-2196	microvasculature	abstract[108]|object[110]	new[108]|new[110]	_	_
14-14	2197-2198	.	_	_	_	_

#Text=Given that numerous systematic and eye diseases are related with the microvascular circulation , OCTA constitutes a relevant new ophthalmic image modality that better aids the diagnosis and monitoring processes of these pathologies .
15-1	2199-2204	Given	_	_	_	_
15-2	2205-2209	that	_	_	_	_
15-3	2210-2218	numerous	abstract[111]	new[111]	coref	16-4[120_111]
15-4	2219-2229	systematic	abstract[111]	new[111]	_	_
15-5	2230-2233	and	abstract[111]	new[111]	_	_
15-6	2234-2237	eye	abstract[111]	new[111]	_	_
15-7	2238-2246	diseases	abstract[111]	new[111]	_	_
15-8	2247-2250	are	_	_	_	_
15-9	2251-2258	related	_	_	_	_
15-10	2259-2263	with	_	_	_	_
15-11	2264-2267	the	abstract[112]	new[112]	_	_
15-12	2268-2281	microvascular	abstract[112]	new[112]	_	_
15-13	2282-2293	circulation	abstract[112]	new[112]	_	_
15-14	2294-2295	,	_	_	_	_
15-15	2296-2300	OCTA	abstract	giv	coref	23-6
15-16	2301-2312	constitutes	_	_	_	_
15-17	2313-2314	a	object[115]	giv[115]	coref	23-5[170_115]
15-18	2315-2323	relevant	object[115]	giv[115]	_	_
15-19	2324-2327	new	object[115]	giv[115]	_	_
15-20	2328-2338	ophthalmic	object[115]	giv[115]	_	_
15-21	2339-2344	image	object|object[115]	giv|giv[115]	coref	23-7
15-22	2345-2353	modality	object[115]	giv[115]	_	_
15-23	2354-2358	that	_	_	_	_
15-24	2359-2365	better	_	_	_	_
15-25	2366-2370	aids	_	_	_	_
15-26	2371-2374	the	abstract[116]|abstract[117]	new[116]|new[117]	coref|coref|coref|coref	27-15[219_116]|27-15[220_117]|27-15[219_116]|27-15[220_117]
15-27	2375-2384	diagnosis	abstract[116]|abstract[117]	new[116]|new[117]	_	_
15-28	2385-2388	and	abstract[117]	new[117]	_	_
15-29	2389-2399	monitoring	abstract[117]	new[117]	_	_
15-30	2400-2409	processes	abstract[117]|abstract[118]	new[117]|giv[118]	_	_
15-31	2410-2412	of	abstract[117]|abstract[118]	new[117]|giv[118]	_	_
15-32	2413-2418	these	abstract[117]|abstract[118]|abstract[119]	new[117]|giv[118]|new[119]	coref	27-20[222_119]
15-33	2419-2430	pathologies	abstract[117]|abstract[118]|abstract[119]	new[117]|giv[118]|new[119]	_	_
15-34	2431-2432	.	_	_	_	_

#Text=As reference , diseases such as diabetes can generate a Diabetic Retinopathy ( DR ) , which provokes microvascular problems in advanced stages of the disease , eventually producing total blindness in the worst case scenario .
16-1	2433-2435	As	_	_	_	_
16-2	2436-2445	reference	_	_	_	_
16-3	2446-2447	,	_	_	_	_
16-4	2448-2456	diseases	abstract[120]	giv[120]	coref	23-26[176_120]
16-5	2457-2461	such	abstract[120]	giv[120]	_	_
16-6	2462-2464	as	abstract[120]	giv[120]	_	_
16-7	2465-2473	diabetes	abstract[120]|abstract	giv[120]|new	_	_
16-8	2474-2477	can	_	_	_	_
16-9	2478-2486	generate	_	_	_	_
16-10	2487-2488	a	abstract[123]	new[123]	appos	16-14[0_123]
16-11	2489-2497	Diabetic	abstract|abstract[123]	new|new[123]	_	_
16-12	2498-2509	Retinopathy	abstract[123]	new[123]	_	_
16-13	2510-2511	(	_	_	_	_
16-14	2512-2514	DR	abstract	giv	coref	16-25[127_0]
16-15	2515-2516	)	_	_	_	_
16-16	2517-2518	,	_	_	_	_
16-17	2519-2524	which	_	_	_	_
16-18	2525-2533	provokes	_	_	_	_
16-19	2534-2547	microvascular	abstract[125]	new[125]	_	_
16-20	2548-2556	problems	abstract[125]	new[125]	_	_
16-21	2557-2559	in	abstract[125]	new[125]	_	_
16-22	2560-2568	advanced	abstract[125]|abstract[126]	new[125]|new[126]	_	_
16-23	2569-2575	stages	abstract[125]|abstract[126]	new[125]|new[126]	_	_
16-24	2576-2578	of	abstract[125]|abstract[126]	new[125]|new[126]	_	_
16-25	2579-2582	the	abstract[125]|abstract[126]|abstract[127]	new[125]|new[126]|giv[127]	coref	24-26[0_127]
16-26	2583-2590	disease	abstract[125]|abstract[126]|abstract[127]	new[125]|new[126]|giv[127]	_	_
16-27	2591-2592	,	_	_	_	_
16-28	2593-2603	eventually	_	_	_	_
16-29	2604-2613	producing	_	_	_	_
16-30	2614-2619	total	abstract[128]	new[128]	_	_
16-31	2620-2629	blindness	abstract[128]	new[128]	_	_
16-32	2630-2632	in	abstract[128]	new[128]	_	_
16-33	2633-2636	the	abstract[128]|event[130]	new[128]|new[130]	_	_
16-34	2637-2642	worst	abstract[128]|event[130]	new[128]|new[130]	_	_
16-35	2643-2647	case	abstract[128]|abstract|event[130]	new[128]|new|new[130]	_	_
16-36	2648-2656	scenario	abstract[128]|event[130]	new[128]|new[130]	_	_
16-37	2657-2658	.	_	_	_	_

#Text=Also , the Retinal Vein Occlusion ( RVO ) produces a problematic loss of vascularity and a progressive vision loss .
17-1	2659-2663	Also	_	_	_	_
17-2	2664-2665	,	_	_	_	_
17-3	2666-2669	the	abstract[133]	new[133]	appos	17-8[0_133]
17-4	2670-2677	Retinal	person|abstract[133]	new|new[133]	_	_
17-5	2678-2682	Vein	plant|abstract[133]	new|new[133]	_	_
17-6	2683-2692	Occlusion	abstract[133]	new[133]	_	_
17-7	2693-2694	(	_	_	_	_
17-8	2695-2698	RVO	abstract	giv	coref	24-28
17-9	2699-2700	)	_	_	_	_
17-10	2701-2709	produces	_	_	_	_
17-11	2710-2711	a	abstract[135]	new[135]	_	_
17-12	2712-2723	problematic	abstract[135]	new[135]	_	_
17-13	2724-2728	loss	abstract[135]	new[135]	_	_
17-14	2729-2731	of	abstract[135]	new[135]	_	_
17-15	2732-2743	vascularity	abstract[135]|object	new[135]|new	ana	18-9
17-16	2744-2747	and	abstract[135]	new[135]	_	_
17-17	2748-2749	a	abstract[135]|abstract[138]	new[135]|new[138]	_	_
17-18	2750-2761	progressive	abstract[135]|abstract[138]	new[135]|new[138]	_	_
17-19	2762-2768	vision	abstract[135]|abstract|abstract[138]	new[135]|giv|new[138]	coref	31-18[277_0]
17-20	2769-2773	loss	abstract[135]|abstract[138]	new[135]|new[138]	_	_
17-21	2774-2775	.	_	_	_	_

#Text=With these representative examples among many others , it is clear that the retinal vascular integrity is related with the Visual Acuity ( VA ) of the patients .
18-1	2776-2780	With	_	_	_	_
18-2	2781-2786	these	abstract[139]	new[139]	_	_
18-3	2787-2801	representative	abstract[139]	new[139]	_	_
18-4	2802-2810	examples	abstract[139]	new[139]	_	_
18-5	2811-2816	among	abstract[139]	new[139]	_	_
18-6	2817-2821	many	abstract[139]|place[140]	new[139]|new[140]	_	_
18-7	2822-2828	others	abstract[139]|place[140]	new[139]|new[140]	_	_
18-8	2829-2830	,	_	_	_	_
18-9	2831-2833	it	object	giv	coref	26-26[211_0]
18-10	2834-2836	is	_	_	_	_
18-11	2837-2842	clear	_	_	_	_
18-12	2843-2847	that	_	_	_	_
18-13	2848-2851	the	abstract[142]	new[142]	_	_
18-14	2852-2859	retinal	abstract[142]	new[142]	_	_
18-15	2860-2868	vascular	abstract[142]	new[142]	_	_
18-16	2869-2878	integrity	abstract[142]	new[142]	_	_
18-17	2879-2881	is	_	_	_	_
18-18	2882-2889	related	_	_	_	_
18-19	2890-2894	with	_	_	_	_
18-20	2895-2898	the	organization[143]	new[143]	appos	18-24[0_143]
18-21	2899-2905	Visual	organization[143]	new[143]	_	_
18-22	2906-2912	Acuity	organization[143]	new[143]	_	_
18-23	2913-2914	(	_	_	_	_
18-24	2915-2917	VA	organization	giv	coref	19-5[146_0]
18-25	2918-2919	)	_	_	_	_
18-26	2920-2922	of	_	_	_	_
18-27	2923-2926	the	person[145]	new[145]	ana	24-8[0_145]
18-28	2927-2935	patients	person[145]	new[145]	_	_
18-29	2936-2937	.	_	_	_	_

#Text=Commonly , to estimate the VA of a given patient , it is necessary to perform different rudimentary tests .
19-1	2938-2946	Commonly	_	_	_	_
19-2	2947-2948	,	_	_	_	_
19-3	2949-2951	to	_	_	_	_
19-4	2952-2960	estimate	_	_	_	_
19-5	2961-2964	the	organization[146]	giv[146]	coref	21-5[0_146]
19-6	2965-2967	VA	organization[146]	giv[146]	_	_
19-7	2968-2970	of	organization[146]	giv[146]	_	_
19-8	2971-2972	a	organization[146]|person[147]	giv[146]|giv[147]	coref	20-16[154_147]
19-9	2973-2978	given	organization[146]|person[147]	giv[146]|giv[147]	_	_
19-10	2979-2986	patient	organization[146]|person[147]	giv[146]|giv[147]	_	_
19-11	2987-2988	,	_	_	_	_
19-12	2989-2991	it	abstract	new	cata	19-12[0_149]
19-13	2992-2994	is	_	_	_	_
19-14	2995-3004	necessary	_	_	_	_
19-15	3005-3007	to	abstract[149]	new[149]	_	_
19-16	3008-3015	perform	abstract[149]	new[149]	_	_
19-17	3016-3025	different	abstract[149]|abstract[150]	new[149]|new[150]	coref	20-4[151_150]
19-18	3026-3037	rudimentary	abstract[149]|abstract[150]	new[149]|new[150]	_	_
19-19	3038-3043	tests	abstract[149]|abstract[150]	new[149]|new[150]	_	_
19-20	3044-3045	.	_	_	_	_

#Text=In particular , these tests are normally related with the analysis of the ability of the patient to observe characteristic objects of different sizes and at different distances .
20-1	3046-3048	In	_	_	_	_
20-2	3049-3059	particular	_	_	_	_
20-3	3060-3061	,	_	_	_	_
20-4	3062-3067	these	abstract[151]	giv[151]	_	_
20-5	3068-3073	tests	abstract[151]	giv[151]	_	_
20-6	3074-3077	are	_	_	_	_
20-7	3078-3086	normally	_	_	_	_
20-8	3087-3094	related	_	_	_	_
20-9	3095-3099	with	_	_	_	_
20-10	3100-3103	the	abstract[152]	new[152]	_	_
20-11	3104-3112	analysis	abstract[152]	new[152]	_	_
20-12	3113-3115	of	abstract[152]	new[152]	_	_
20-13	3116-3119	the	abstract[152]|abstract[153]	new[152]|new[153]	_	_
20-14	3120-3127	ability	abstract[152]|abstract[153]	new[152]|new[153]	_	_
20-15	3128-3130	of	abstract[152]|abstract[153]	new[152]|new[153]	_	_
20-16	3131-3134	the	abstract[152]|abstract[153]|person[154]	new[152]|new[153]|giv[154]	coref	25-17[195_154]
20-17	3135-3142	patient	abstract[152]|abstract[153]|person[154]	new[152]|new[153]|giv[154]	_	_
20-18	3143-3145	to	_	_	_	_
20-19	3146-3153	observe	_	_	_	_
20-20	3154-3168	characteristic	object[155]	new[155]	_	_
20-21	3169-3176	objects	object[155]	new[155]	_	_
20-22	3177-3179	of	object[155]	new[155]	_	_
20-23	3180-3189	different	object[155]|quantity[156]	new[155]|new[156]	_	_
20-24	3190-3195	sizes	object[155]|quantity[156]	new[155]|new[156]	_	_
20-25	3196-3199	and	_	_	_	_
20-26	3200-3202	at	_	_	_	_
20-27	3203-3212	different	quantity[157]	new[157]	_	_
20-28	3213-3222	distances	quantity[157]	new[157]	_	_
20-29	3223-3224	.	_	_	_	_

#Text=Consequently , the final VA estimation is subjective whereas its process is tedious and slow .
21-1	3225-3237	Consequently	_	_	_	_
21-2	3238-3239	,	_	_	_	_
21-3	3240-3243	the	abstract[159]	new[159]	ana	21-10[0_159]
21-4	3244-3249	final	abstract[159]	new[159]	_	_
21-5	3250-3252	VA	organization|abstract[159]	giv|new[159]	coref	24-11[180_0]
21-6	3253-3263	estimation	abstract[159]	new[159]	_	_
21-7	3264-3266	is	_	_	_	_
21-8	3267-3277	subjective	_	_	_	_
21-9	3278-3285	whereas	_	_	_	_
21-10	3286-3289	its	abstract|event[161]	giv|giv[161]	coref|coref	22-12[165_161]|22-12[165_161]
21-11	3290-3297	process	event[161]	giv[161]	_	_
21-12	3298-3300	is	_	_	_	_
21-13	3301-3308	tedious	_	_	_	_
21-14	3309-3312	and	_	_	_	_
21-15	3313-3317	slow	_	_	_	_
21-16	3318-3319	.	_	_	_	_

#Text=In that context , any technological contribution that avoids or facilitates this revision process is extremely desired in the ophthalmic field .
22-1	3320-3322	In	_	_	_	_
22-2	3323-3327	that	abstract[162]	new[162]	_	_
22-3	3328-3335	context	abstract[162]	new[162]	_	_
22-4	3336-3337	,	_	_	_	_
22-5	3338-3341	any	abstract[163]	new[163]	_	_
22-6	3342-3355	technological	abstract[163]	new[163]	_	_
22-7	3356-3368	contribution	abstract[163]	new[163]	_	_
22-8	3369-3373	that	_	_	_	_
22-9	3374-3380	avoids	_	_	_	_
22-10	3381-3383	or	_	_	_	_
22-11	3384-3395	facilitates	_	_	_	_
22-12	3396-3400	this	event[165]	giv[165]	_	_
22-13	3401-3409	revision	abstract|event[165]	new|giv[165]	_	_
22-14	3410-3417	process	event[165]	giv[165]	_	_
22-15	3418-3420	is	_	_	_	_
22-16	3421-3430	extremely	_	_	_	_
22-17	3431-3438	desired	_	_	_	_
22-18	3439-3441	in	_	_	_	_
22-19	3442-3445	the	abstract[166]	new[166]	coref	30-59[260_166]
22-20	3446-3456	ophthalmic	abstract[166]	new[166]	_	_
22-21	3457-3462	field	abstract[166]	new[166]	_	_
22-22	3463-3464	.	_	_	_	_

#Text=Given the potential of the OCTA image modality , over recent years , several clinical studies were published demonstrating its utility in the analysis of different vascular diseases .
23-1	3465-3470	Given	_	_	_	_
23-2	3471-3474	the	abstract[167]	new[167]	ana	23-20[0_167]
23-3	3475-3484	potential	abstract[167]	new[167]	_	_
23-4	3485-3487	of	abstract[167]	new[167]	_	_
23-5	3488-3491	the	abstract[167]|object[170]	new[167]|giv[170]	coref	27-22[224_170]
23-6	3492-3496	OCTA	abstract[167]|abstract|object[170]	new[167]|giv|giv[170]	coref	25-11
23-7	3497-3502	image	abstract[167]|object|object[170]	new[167]|giv|giv[170]	coref	27-23
23-8	3503-3511	modality	abstract[167]|object[170]	new[167]|giv[170]	_	_
23-9	3512-3513	,	abstract[167]	new[167]	_	_
23-10	3514-3518	over	abstract[167]	new[167]	_	_
23-11	3519-3525	recent	abstract[167]|time[171]	new[167]|new[171]	_	_
23-12	3526-3531	years	abstract[167]|time[171]	new[167]|new[171]	_	_
23-13	3532-3533	,	_	_	_	_
23-14	3534-3541	several	abstract[172]	new[172]	coref	25-1[189_172]
23-15	3542-3550	clinical	abstract[172]	new[172]	_	_
23-16	3551-3558	studies	abstract[172]	new[172]	_	_
23-17	3559-3563	were	_	_	_	_
23-18	3564-3573	published	_	_	_	_
23-19	3574-3587	demonstrating	_	_	_	_
23-20	3588-3591	its	abstract|abstract[174]	giv|new[174]	_	_
23-21	3592-3599	utility	abstract[174]	new[174]	_	_
23-22	3600-3602	in	_	_	_	_
23-23	3603-3606	the	abstract[175]	new[175]	coref	28-27[233_175]
23-24	3607-3615	analysis	abstract[175]	new[175]	_	_
23-25	3616-3618	of	abstract[175]	new[175]	_	_
23-26	3619-3628	different	abstract[175]|abstract[176]	new[175]|giv[176]	coref	24-28[188_176]
23-27	3629-3637	vascular	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
23-28	3638-3646	diseases	abstract[175]|abstract[176]	new[175]|giv[176]	_	_
23-29	3647-3648	.	_	_	_	_

#Text=Hence , Balaratnasingam et al. demonstrated in their study that the VA is correlated with the Foveal Avascular Zone ( FAZ ) in patients with DR and RVO diseases .
24-1	3649-3654	Hence	_	_	_	_
24-2	3655-3656	,	_	_	_	_
24-3	3657-3672	Balaratnasingam	person	new	_	_
24-4	3673-3675	et	_	_	_	_
24-5	3676-3679	al.	_	_	_	_
24-6	3680-3692	demonstrated	_	_	_	_
24-7	3693-3695	in	_	_	_	_
24-8	3696-3701	their	person|abstract[179]	giv|new[179]	coref|coref|coref|coref	24-24[185_0]|30-23[247_179]|24-24[185_0]|30-23[247_179]
24-9	3702-3707	study	abstract[179]	new[179]	_	_
24-10	3708-3712	that	_	_	_	_
24-11	3713-3716	the	organization[180]	giv[180]	coref	25-14[194_180]
24-12	3717-3719	VA	organization[180]	giv[180]	_	_
24-13	3720-3722	is	_	_	_	_
24-14	3723-3733	correlated	_	_	_	_
24-15	3734-3738	with	_	_	_	_
24-16	3739-3742	the	abstract[183]	new[183]	appos	24-21[0_183]
24-17	3743-3749	Foveal	place|abstract[183]	giv|new[183]	_	_
24-18	3750-3759	Avascular	abstract|abstract[183]	new|new[183]	_	_
24-19	3760-3764	Zone	abstract[183]	new[183]	_	_
24-20	3765-3766	(	_	_	_	_
24-21	3767-3770	FAZ	abstract	giv	coref	30-12[241_0]
24-22	3771-3772	)	_	_	_	_
24-23	3773-3775	in	_	_	_	_
24-24	3776-3784	patients	person[185]	giv[185]	_	_
24-25	3785-3789	with	person[185]	giv[185]	_	_
24-26	3790-3792	DR	person[185]|place	giv[185]|giv	coref	26-11[206_0]
24-27	3793-3796	and	person[185]	giv[185]	_	_
24-28	3797-3800	RVO	person[185]|object|abstract[188]	giv[185]|giv|giv[188]	_	_
24-29	3801-3809	diseases	person[185]|abstract[188]	giv[185]|giv[188]	_	_
24-30	3810-3811	.	_	_	_	_

#Text=Other clinical studies related different manual biomarkers extracted from the OCTA images with the VA of the patient . Wei et al. demonstrated the adequate repeatability of the vascular density as representative biomarker in healthy subjects in both macular and optic disk regions .
25-1	3812-3817	Other	abstract[189]	giv[189]	_	_
25-2	3818-3826	clinical	abstract[189]	giv[189]	_	_
25-3	3827-3834	studies	abstract[189]	giv[189]	_	_
25-4	3835-3842	related	_	_	_	_
25-5	3843-3852	different	abstract[191]	new[191]	coref	28-14[227_191]
25-6	3853-3859	manual	object|abstract[191]	giv|new[191]	_	_
25-7	3860-3870	biomarkers	abstract[191]	new[191]	_	_
25-8	3871-3880	extracted	_	_	_	_
25-9	3881-3885	from	_	_	_	_
25-10	3886-3889	the	object[193]	giv[193]	coref	28-17[229_193]
25-11	3890-3894	OCTA	object|object[193]	giv|giv[193]	coref	28-18
25-12	3895-3901	images	object[193]	giv[193]	_	_
25-13	3902-3906	with	object[193]	giv[193]	_	_
25-14	3907-3910	the	object[193]|organization[194]	giv[193]|giv[194]	_	_
25-15	3911-3913	VA	object[193]|organization[194]	giv[193]|giv[194]	_	_
25-16	3914-3916	of	object[193]|organization[194]	giv[193]|giv[194]	_	_
25-17	3917-3920	the	object[193]|organization[194]|person[195]	giv[193]|giv[194]|giv[195]	_	_
25-18	3921-3928	patient	object[193]|organization[194]|person[195]	giv[193]|giv[194]|giv[195]	_	_
25-19	3929-3930	.	_	_	_	_
25-20	3931-3934	Wei	person	new	coref	31-25
25-21	3935-3937	et	_	_	_	_
25-22	3938-3941	al.	_	_	_	_
25-23	3942-3954	demonstrated	_	_	_	_
25-24	3955-3958	the	abstract[197]	giv[197]	_	_
25-25	3959-3967	adequate	abstract[197]	giv[197]	_	_
25-26	3968-3981	repeatability	abstract[197]	giv[197]	_	_
25-27	3982-3984	of	abstract[197]	giv[197]	_	_
25-28	3985-3988	the	abstract[197]|abstract[198]	giv[197]|new[198]	coref	29-17[237_198]
25-29	3989-3997	vascular	abstract[197]|abstract[198]	giv[197]|new[198]	_	_
25-30	3998-4005	density	abstract[197]|abstract[198]	giv[197]|new[198]	_	_
25-31	4006-4008	as	abstract[197]	giv[197]	_	_
25-32	4009-4023	representative	abstract[197]	giv[197]	_	_
25-33	4024-4033	biomarker	abstract[197]	giv[197]	_	_
25-34	4034-4036	in	abstract[197]	giv[197]	_	_
25-35	4037-4044	healthy	abstract[197]|abstract[199]	giv[197]|new[199]	_	_
25-36	4045-4053	subjects	abstract[197]|abstract[199]	giv[197]|new[199]	_	_
25-37	4054-4056	in	abstract[197]|abstract[199]	giv[197]|new[199]	_	_
25-38	4057-4061	both	abstract[197]|abstract[199]|place[200]	giv[197]|new[199]|new[200]	_	_
25-39	4062-4069	macular	abstract[197]|abstract[199]|place[200]	giv[197]|new[199]|new[200]	_	_
25-40	4070-4073	and	abstract[197]|abstract[199]	giv[197]|new[199]	_	_
25-41	4074-4079	optic	abstract[197]|abstract[199]|place[202]	giv[197]|new[199]|new[202]	_	_
25-42	4080-4084	disk	abstract[197]|abstract[199]|object|place[202]	giv[197]|new[199]|new|new[202]	_	_
25-43	4085-4092	regions	abstract[197]|abstract[199]|place[202]	giv[197]|new[199]|new[202]	_	_
25-44	4093-4094	.	_	_	_	_

#Text=Posteriorly , Vivien at al. , demonstrated the influence of the glaucoma disease over the vessel tree characteristics , obtaining as conclusions the absence of retinal vascularity in the pathological cases over a control group .
26-1	4095-4106	Posteriorly	_	_	_	_
26-2	4107-4108	,	_	_	_	_
26-3	4109-4115	Vivien	person[203]	new[203]	_	_
26-4	4116-4118	at	person[203]	new[203]	_	_
26-5	4119-4122	al.	person[203]	new[203]	_	_
26-6	4123-4124	,	_	_	_	_
26-7	4125-4137	demonstrated	_	_	_	_
26-8	4138-4141	the	abstract[204]	new[204]	_	_
26-9	4142-4151	influence	abstract[204]	new[204]	_	_
26-10	4152-4154	of	abstract[204]	new[204]	_	_
26-11	4155-4158	the	abstract[204]|abstract[206]	new[204]|giv[206]	coref	30-17[0_206]
26-12	4159-4167	glaucoma	abstract[204]|abstract|abstract[206]	new[204]|new|giv[206]	_	_
26-13	4168-4175	disease	abstract[204]|abstract[206]	new[204]|giv[206]	_	_
26-14	4176-4180	over	abstract[204]|abstract[206]	new[204]|giv[206]	_	_
26-15	4181-4184	the	abstract[204]|abstract[206]|abstract[209]	new[204]|giv[206]|giv[209]	_	_
26-16	4185-4191	vessel	abstract[204]|abstract[206]|object|abstract[209]	new[204]|giv[206]|new|giv[209]	coref	30-48
26-17	4192-4196	tree	abstract[204]|abstract[206]|plant|abstract[209]	new[204]|giv[206]|new|giv[209]	_	_
26-18	4197-4212	characteristics	abstract[204]|abstract[206]|abstract[209]	new[204]|giv[206]|giv[209]	_	_
26-19	4213-4214	,	_	_	_	_
26-20	4215-4224	obtaining	_	_	_	_
26-21	4225-4227	as	_	_	_	_
26-22	4228-4239	conclusions	_	_	_	_
26-23	4240-4243	the	abstract[210]	new[210]	_	_
26-24	4244-4251	absence	abstract[210]	new[210]	_	_
26-25	4252-4254	of	abstract[210]	new[210]	_	_
26-26	4255-4262	retinal	abstract[210]|abstract[211]	new[210]|giv[211]	ana	27-2[0_211]
26-27	4263-4274	vascularity	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
26-28	4275-4277	in	abstract[210]|abstract[211]	new[210]|giv[211]	_	_
26-29	4278-4281	the	abstract[210]|abstract[211]|abstract[212]	new[210]|giv[211]|new[212]	_	_
26-30	4282-4294	pathological	abstract[210]|abstract[211]|abstract[212]	new[210]|giv[211]|new[212]	_	_
26-31	4295-4300	cases	abstract[210]|abstract[211]|abstract[212]	new[210]|giv[211]|new[212]	_	_
26-32	4301-4305	over	abstract[210]|abstract[211]|abstract[212]	new[210]|giv[211]|new[212]	_	_
26-33	4306-4307	a	abstract[210]|abstract[211]|abstract[212]|person[214]	new[210]|giv[211]|new[212]|new[214]	_	_
26-34	4308-4315	control	abstract[210]|abstract[211]|abstract[212]|abstract|person[214]	new[210]|giv[211]|new[212]|new|new[214]	_	_
26-35	4316-4321	group	abstract[210]|abstract[211]|abstract[212]|person[214]	new[210]|giv[211]|new[212]|new[214]	_	_
26-36	4322-4323	.	_	_	_	_

#Text=Given its novelty , there exists a limited number of computational proposals to aid the diagnosis and monitoring of pathologies with this image modality .
27-1	4324-4329	Given	_	_	_	_
27-2	4330-4333	its	abstract|abstract[216]	giv|new[216]	_	_
27-3	4334-4341	novelty	abstract[216]	new[216]	_	_
27-4	4342-4343	,	_	_	_	_
27-5	4344-4349	there	_	_	_	_
27-6	4350-4356	exists	_	_	_	_
27-7	4357-4358	a	abstract[217]	new[217]	_	_
27-8	4359-4366	limited	abstract[217]	new[217]	_	_
27-9	4367-4373	number	abstract[217]	new[217]	_	_
27-10	4374-4376	of	abstract[217]	new[217]	_	_
27-11	4377-4390	computational	abstract[217]|abstract[218]	new[217]|new[218]	_	_
27-12	4391-4400	proposals	abstract[217]|abstract[218]	new[217]|new[218]	_	_
27-13	4401-4403	to	_	_	_	_
27-14	4404-4407	aid	_	_	_	_
27-15	4408-4411	the	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
27-16	4412-4421	diagnosis	abstract[219]|abstract[220]	giv[219]|giv[220]	_	_
27-17	4422-4425	and	abstract[220]	giv[220]	_	_
27-18	4426-4436	monitoring	abstract[220]|event[221]	giv[220]|new[221]	_	_
27-19	4437-4439	of	abstract[220]|event[221]	giv[220]|new[221]	_	_
27-20	4440-4451	pathologies	abstract[220]|event[221]|abstract[222]	giv[220]|new[221]|giv[222]	_	_
27-21	4452-4456	with	abstract[220]|event[221]|abstract[222]	giv[220]|new[221]|giv[222]	_	_
27-22	4457-4461	this	abstract[220]|event[221]|abstract[222]|object[224]	giv[220]|new[221]|giv[222]|giv[224]	_	_
27-23	4462-4467	image	abstract[220]|event[221]|abstract[222]|object|object[224]	giv[220]|new[221]|giv[222]|giv|giv[224]	coref	28-23
27-24	4468-4476	modality	abstract[220]|event[221]|abstract[222]|object[224]	giv[220]|new[221]|giv[222]|giv[224]	_	_
27-25	4477-4478	.	_	_	_	_

#Text=In fact , the existing works are mainly based on the extraction of characteristic biomarkers in the OCTA images or improving the image quality to facilitate its posterior analysis .
28-1	4479-4481	In	_	_	_	_
28-2	4482-4486	fact	_	_	_	_
28-3	4487-4488	,	_	_	_	_
28-4	4489-4492	the	abstract[225]	new[225]	_	_
28-5	4493-4501	existing	abstract[225]	new[225]	_	_
28-6	4502-4507	works	abstract[225]	new[225]	_	_
28-7	4508-4511	are	_	_	_	_
28-8	4512-4518	mainly	_	_	_	_
28-9	4519-4524	based	_	_	_	_
28-10	4525-4527	on	_	_	_	_
28-11	4528-4531	the	abstract[226]	new[226]	_	_
28-12	4532-4542	extraction	abstract[226]	new[226]	_	_
28-13	4543-4545	of	abstract[226]	new[226]	_	_
28-14	4546-4560	characteristic	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
28-15	4561-4571	biomarkers	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
28-16	4572-4574	in	abstract[226]|abstract[227]	new[226]|giv[227]	_	_
28-17	4575-4578	the	abstract[226]|abstract[227]|object[229]	new[226]|giv[227]|giv[229]	coref	30-15[244_229]
28-18	4579-4583	OCTA	abstract[226]|abstract[227]|abstract|object[229]	new[226]|giv[227]|giv|giv[229]	coref	30-18
28-19	4584-4590	images	abstract[226]|abstract[227]|object[229]	new[226]|giv[227]|giv[229]	_	_
28-20	4591-4593	or	_	_	_	_
28-21	4594-4603	improving	_	_	_	_
28-22	4604-4607	the	abstract[231]	new[231]	ana	28-27[0_231]
28-23	4608-4613	image	object|abstract[231]	giv|new[231]	_	_
28-24	4614-4621	quality	abstract[231]	new[231]	_	_
28-25	4622-4624	to	_	_	_	_
28-26	4625-4635	facilitate	_	_	_	_
28-27	4636-4639	its	abstract|abstract[233]	giv|giv[233]	coref|coref|coref|coref	31-20[278_233]|31-29[280_0]|31-20[278_233]|31-29[280_0]
28-28	4640-4649	posterior	abstract[233]	giv[233]	_	_
28-29	4650-4658	analysis	abstract[233]	giv[233]	_	_
28-30	4659-4660	.	_	_	_	_

#Text=As reference , Díaz et al. briefly introduced a method to automatically extract and measure generally the Vascular Density ( VD ) .
29-1	4661-4663	As	_	_	_	_
29-2	4664-4673	reference	_	_	_	_
29-3	4674-4675	,	_	_	_	_
29-4	4676-4680	Díaz	person	new	_	_
29-5	4681-4683	et	_	_	_	_
29-6	4684-4687	al.	_	_	_	_
29-7	4688-4695	briefly	_	_	_	_
29-8	4696-4706	introduced	_	_	_	_
29-9	4707-4708	a	abstract[235]	new[235]	coref	30-6[240_235]
29-10	4709-4715	method	abstract[235]	new[235]	_	_
29-11	4716-4718	to	_	_	_	_
29-12	4719-4732	automatically	_	_	_	_
29-13	4733-4740	extract	_	_	_	_
29-14	4741-4744	and	_	_	_	_
29-15	4745-4752	measure	_	_	_	_
29-16	4753-4762	generally	_	_	_	_
29-17	4763-4766	the	abstract[237]	giv[237]	appos	29-21[0_237]
29-18	4767-4775	Vascular	abstract|abstract[237]	new|giv[237]	_	_
29-19	4776-4783	Density	abstract[237]	giv[237]	_	_
29-20	4784-4785	(	_	_	_	_
29-21	4786-4788	VD	abstract	giv	coref	30-68[263_0]
29-22	4789-4790	)	_	_	_	_
29-23	4791-4792	.	_	_	_	_

#Text=Also , the authors proposed a method to extract and measure the FAZ in healthy and DR OCTA images and they performed a FAZ circularity study in healthy and pathological images . Alam et al. proposed different features extracted from the OCTA images , namely , the vessel tortuosity , the mean diameter of the blood vessels , the semi-automatic FAZ area , the FAZ irregularity and the density of the parafoveal avascular region using fractal dimensions . Guo et al. segmented and quantified avascular ischemic zones with map probabilities that were extracted by a deep convolutional neural network . Wang et al.
30-1	4793-4797	Also	_	_	_	_
30-2	4798-4799	,	_	_	_	_
30-3	4800-4803	the	person[239]	new[239]	ana	30-21[0_239]
30-4	4804-4811	authors	person[239]	new[239]	_	_
30-5	4812-4820	proposed	_	_	_	_
30-6	4821-4822	a	abstract[240]	giv[240]	coref	31-2[272_240]
30-7	4823-4829	method	abstract[240]	giv[240]	_	_
30-8	4830-4832	to	_	_	_	_
30-9	4833-4840	extract	_	_	_	_
30-10	4841-4844	and	_	_	_	_
30-11	4845-4852	measure	_	_	_	_
30-12	4853-4856	the	abstract[241]	giv[241]	coref	30-61[0_241]
30-13	4857-4860	FAZ	abstract[241]	giv[241]	_	_
30-14	4861-4863	in	abstract[241]	giv[241]	_	_
30-15	4864-4871	healthy	abstract[241]|object[244]	giv[241]|giv[244]	coref	30-28[248_244]
30-16	4872-4875	and	abstract[241]|object[244]	giv[241]|giv[244]	_	_
30-17	4876-4878	DR	abstract[241]|place|object[244]	giv[241]|giv|giv[244]	_	_
30-18	4879-4883	OCTA	abstract[241]|abstract|object[244]	giv[241]|giv|giv[244]	coref	30-42
30-19	4884-4890	images	abstract[241]|object[244]	giv[241]|giv[244]	_	_
30-20	4891-4894	and	_	_	_	_
30-21	4895-4899	they	person	giv	ana	31-36
30-22	4900-4909	performed	_	_	_	_
30-23	4910-4911	a	abstract[247]	giv[247]	_	_
30-24	4912-4915	FAZ	abstract[247]	giv[247]	_	_
30-25	4916-4927	circularity	abstract|abstract[247]	new|giv[247]	_	_
30-26	4928-4933	study	abstract[247]	giv[247]	_	_
30-27	4934-4936	in	abstract[247]	giv[247]	_	_
30-28	4937-4944	healthy	abstract[247]|object[248]	giv[247]|giv[248]	coref	30-41[252_248]
30-29	4945-4948	and	abstract[247]|object[248]	giv[247]|giv[248]	_	_
30-30	4949-4961	pathological	abstract[247]|object[248]	giv[247]|giv[248]	_	_
30-31	4962-4968	images	abstract[247]|object[248]	giv[247]|giv[248]	_	_
30-32	4969-4970	.	_	_	_	_
30-33	4971-4975	Alam	person	new	_	_
30-34	4976-4978	et	_	_	_	_
30-35	4979-4982	al.	_	_	_	_
30-36	4983-4991	proposed	_	_	_	_
30-37	4992-5001	different	abstract[250]	new[250]	_	_
30-38	5002-5010	features	abstract[250]	new[250]	_	_
30-39	5011-5020	extracted	_	_	_	_
30-40	5021-5025	from	_	_	_	_
30-41	5026-5029	the	object[252]	giv[252]	appos	30-45[255_252]
30-42	5030-5034	OCTA	abstract|object[252]	giv|giv[252]	coref	31-10
30-43	5035-5041	images	object[252]	giv[252]	_	_
30-44	5042-5043	,	_	_	_	_
30-45	5044-5050	namely	abstract[254]|object[255]	new[254]|giv[255]	coref|coref	31-8[275_255]|31-8[275_255]
30-46	5051-5052	,	abstract[254]|object[255]	new[254]|giv[255]	_	_
30-47	5053-5056	the	abstract[254]|object[255]	new[254]|giv[255]	_	_
30-48	5057-5063	vessel	object|abstract[254]|object[255]	giv|new[254]|giv[255]	_	_
30-49	5064-5074	tortuosity	abstract[254]|object[255]	new[254]|giv[255]	_	_
30-50	5075-5076	,	object[255]	giv[255]	_	_
30-51	5077-5080	the	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-52	5081-5085	mean	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-53	5086-5094	diameter	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-54	5095-5097	of	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-55	5098-5101	the	object[255]|abstract[256]|object[258]	giv[255]|new[256]|new[258]	_	_
30-56	5102-5107	blood	object[255]|abstract[256]|substance|object[258]	giv[255]|new[256]|giv|new[258]	_	_
30-57	5108-5115	vessels	object[255]|abstract[256]|object[258]	giv[255]|new[256]|new[258]	_	_
30-58	5116-5117	,	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-59	5118-5121	the	object[255]|abstract[256]|abstract[260]	giv[255]|new[256]|giv[260]	coref	31-14[276_260]
30-60	5122-5136	semi-automatic	object[255]|abstract[256]|abstract[260]	giv[255]|new[256]|giv[260]	_	_
30-61	5137-5140	FAZ	object[255]|abstract[256]|abstract|abstract[260]	giv[255]|new[256]|giv|giv[260]	coref	30-65
30-62	5141-5145	area	object[255]|abstract[256]|abstract[260]	giv[255]|new[256]|giv[260]	_	_
30-63	5146-5147	,	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-64	5148-5151	the	object[255]|abstract[256]|abstract[262]	giv[255]|new[256]|new[262]	_	_
30-65	5152-5155	FAZ	object[255]|abstract[256]|abstract|abstract[262]	giv[255]|new[256]|giv|new[262]	_	_
30-66	5156-5168	irregularity	object[255]|abstract[256]|abstract[262]	giv[255]|new[256]|new[262]	_	_
30-67	5169-5172	and	object[255]|abstract[256]	giv[255]|new[256]	_	_
30-68	5173-5176	the	object[255]|abstract[256]|abstract[263]	giv[255]|new[256]|giv[263]	_	_
30-69	5177-5184	density	object[255]|abstract[256]|abstract[263]	giv[255]|new[256]|giv[263]	_	_
30-70	5185-5187	of	object[255]|abstract[256]|abstract[263]	giv[255]|new[256]|giv[263]	_	_
30-71	5188-5191	the	object[255]|abstract[256]|abstract[263]|place[264]	giv[255]|new[256]|giv[263]|giv[264]	_	_
30-72	5192-5202	parafoveal	object[255]|abstract[256]|abstract[263]|place[264]	giv[255]|new[256]|giv[263]|giv[264]	_	_
30-73	5203-5212	avascular	object[255]|abstract[256]|abstract[263]|place[264]	giv[255]|new[256]|giv[263]|giv[264]	_	_
30-74	5213-5219	region	object[255]|abstract[256]|abstract[263]|place[264]	giv[255]|new[256]|giv[263]|giv[264]	_	_
30-75	5220-5225	using	_	_	_	_
30-76	5226-5233	fractal	abstract[265]	new[265]	_	_
30-77	5234-5244	dimensions	abstract[265]	new[265]	_	_
30-78	5245-5246	.	_	_	_	_
30-79	5247-5250	Guo	person	new	_	_
30-80	5251-5253	et	_	_	_	_
30-81	5254-5257	al.	_	_	_	_
30-82	5258-5267	segmented	_	_	_	_
30-83	5268-5271	and	_	_	_	_
30-84	5272-5282	quantified	_	_	_	_
30-85	5283-5292	avascular	place[267]	new[267]	_	_
30-86	5293-5301	ischemic	place[267]	new[267]	_	_
30-87	5302-5307	zones	place[267]	new[267]	_	_
30-88	5308-5312	with	place[267]	new[267]	_	_
30-89	5313-5316	map	place[267]|object|abstract[269]	new[267]|new|new[269]	_	_
30-90	5317-5330	probabilities	place[267]|abstract[269]	new[267]|new[269]	_	_
30-91	5331-5335	that	_	_	_	_
30-92	5336-5340	were	_	_	_	_
30-93	5341-5350	extracted	_	_	_	_
30-94	5351-5353	by	_	_	_	_
30-95	5354-5355	a	abstract[270]	new[270]	_	_
30-96	5356-5360	deep	abstract[270]	new[270]	_	_
30-97	5361-5374	convolutional	abstract[270]	new[270]	_	_
30-98	5375-5381	neural	abstract[270]	new[270]	_	_
30-99	5382-5389	network	abstract[270]	new[270]	_	_
30-100	5390-5391	.	_	_	_	_
30-101	5392-5396	Wang	person	new	_	_
30-102	5397-5399	et	_	_	_	_
30-103	5400-5403	al.	_	_	_	_

#Text=proposed a method to produce mosaics using different overlapping OCTA images , increasing the wide field of vision for the posterior clinical analysis . Wei et al. improved the quality of the OCTA scans in their work whereas Camino et al. identified existing shadow artifacts that typically appear in the OCTA images to improve the visualization and facilitate their inspection .
31-1	5404-5412	proposed	_	_	_	_
31-2	5413-5414	a	abstract[272]	giv[272]	_	_
31-3	5415-5421	method	abstract[272]	giv[272]	_	_
31-4	5422-5424	to	_	_	_	_
31-5	5425-5432	produce	_	_	_	_
31-6	5433-5440	mosaics	object	new	_	_
31-7	5441-5446	using	_	_	_	_
31-8	5447-5456	different	object[275]	giv[275]	coref	31-50[289_275]
31-9	5457-5468	overlapping	object[275]	giv[275]	_	_
31-10	5469-5473	OCTA	abstract|object[275]	giv|giv[275]	coref	31-33
31-11	5474-5480	images	object[275]	giv[275]	_	_
31-12	5481-5482	,	_	_	_	_
31-13	5483-5493	increasing	_	_	_	_
31-14	5494-5497	the	abstract[276]	giv[276]	_	_
31-15	5498-5502	wide	abstract[276]	giv[276]	_	_
31-16	5503-5508	field	abstract[276]	giv[276]	_	_
31-17	5509-5511	of	abstract[276]	giv[276]	_	_
31-18	5512-5518	vision	abstract[276]|abstract[277]	giv[276]|giv[277]	_	_
31-19	5519-5522	for	abstract[276]|abstract[277]	giv[276]|giv[277]	_	_
31-20	5523-5526	the	abstract[276]|abstract[277]|abstract[278]	giv[276]|giv[277]|giv[278]	_	_
31-21	5527-5536	posterior	abstract[276]|abstract[277]|abstract[278]	giv[276]|giv[277]|giv[278]	_	_
31-22	5537-5545	clinical	abstract[276]|abstract[277]|abstract[278]	giv[276]|giv[277]|giv[278]	_	_
31-23	5546-5554	analysis	abstract[276]|abstract[277]|abstract[278]	giv[276]|giv[277]|giv[278]	_	_
31-24	5555-5556	.	_	_	_	_
31-25	5557-5560	Wei	person	giv	_	_
31-26	5561-5563	et	_	_	_	_
31-27	5564-5567	al.	_	_	_	_
31-28	5568-5576	improved	_	_	_	_
31-29	5577-5580	the	abstract[280]	giv[280]	_	_
31-30	5581-5588	quality	abstract[280]	giv[280]	_	_
31-31	5589-5591	of	abstract[280]	giv[280]	_	_
31-32	5592-5595	the	abstract[280]|event[282]	giv[280]|new[282]	_	_
31-33	5596-5600	OCTA	abstract[280]|abstract|event[282]	giv[280]|giv|new[282]	coref	31-51
31-34	5601-5606	scans	abstract[280]|event[282]	giv[280]|new[282]	_	_
31-35	5607-5609	in	abstract[280]|event[282]	giv[280]|new[282]	_	_
31-36	5610-5615	their	abstract[280]|event[282]|person|abstract[284]	giv[280]|new[282]|giv|new[284]	ana|ana	31-59|31-59
31-37	5616-5620	work	abstract[280]|event[282]|abstract[284]	giv[280]|new[282]|new[284]	_	_
31-38	5621-5628	whereas	_	_	_	_
31-39	5629-5635	Camino	person	new	_	_
31-40	5636-5638	et	_	_	_	_
31-41	5639-5642	al.	_	_	_	_
31-42	5643-5653	identified	_	_	_	_
31-43	5654-5662	existing	abstract[287]	new[287]	_	_
31-44	5663-5669	shadow	abstract|abstract[287]	new|new[287]	_	_
31-45	5670-5679	artifacts	abstract[287]	new[287]	_	_
31-46	5680-5684	that	_	_	_	_
31-47	5685-5694	typically	_	_	_	_
31-48	5695-5701	appear	_	_	_	_
31-49	5702-5704	in	_	_	_	_
31-50	5705-5708	the	object[289]	giv[289]	_	_
31-51	5709-5713	OCTA	abstract|object[289]	giv|giv[289]	_	_
31-52	5714-5720	images	object[289]	giv[289]	_	_
31-53	5721-5723	to	_	_	_	_
31-54	5724-5731	improve	_	_	_	_
31-55	5732-5735	the	abstract[290]	giv[290]	_	_
31-56	5736-5749	visualization	abstract[290]	giv[290]	_	_
31-57	5750-5753	and	_	_	_	_
31-58	5754-5764	facilitate	_	_	_	_
31-59	5765-5770	their	person|abstract[292]	giv|new[292]	_	_
31-60	5771-5781	inspection	abstract[292]	new[292]	_	_
31-61	5782-5783	.	_	_	_	_
